Welcome to Lawsuit.com  

Our mission is to provide each client with the most effective ethical representation possible, and to preserve and promote the civil justice system.

Marketing of Trasylol Suspended

Posted on April 29, 2008

Bayer Pharmaceuticals has suspended the marketing of Trasylol (aprotinin) which is used to reduce perioperative blood loss during cardiac surgery with cardiopulmonary bypass. Preliminary results of a Canadian study indicate that while patients given Trasylol experience fewer serious bleeding events, they may also have a greater risk of death than patients taking either of two other antifibrinolytic drugs.

Sales of Trasylol will be suspended until FDA can conduct a thorough analysis of the study and gain a better understanding of the risks and benefits of the drug. Because there are few treatment options for patients at risk for excessive bleeding during cardiac surgery, FDA is working with Bayer to gradually phase Trasylol out of the marketplace so that it doesn't cause shortages of other drugs used for this purpose.

FDA is also exploring ways that physicians may continue to have access to Trasylol in specific cases where the benefits of the drug outweigh the risks.

Additional Information:

FDA MedWatch Safety Alert. Trasylol (aprotinin injection). November 5, 2007.
http://www.fda.gov/medwatch/safety/2007/safety07.htm#Trasylol

Lawsuit Membership
Law firms interested in becoming part of this unique legal community should apply here.Join Lawsuit.com

Lawsuit Video Tips
To become a participating member of Lawsuit.com you must supply a video about your firm, talk about the litigation you find important, and how you help your clients. For ideas and video tips on effective videos click here. Video Creation Tips

Become an Editor
Lawsuit.com is currently building one of the largest human-edited legal video databases in the Web 2.0 World. Want to help? Apply here to become an Editor.Comment